June 3, 2018 Combining pembrolizumab with conventional chemotherapy in the first-line setting significantly prolongs median overall survival (OS) in patients with metastatic squamous non–small cell lung cancer (NSCLC), according to data from the global phase III KEYNOTE-407 trial presented during the “Compelling Combinations: Raising the Bar With Immunotherapy” Clinical Science Symposium, held June 3...
Pro zobrazení tohoto obsahu je třeba být přihlášen.